Seventeen percent to twenty-five percent of pancreatic cancers harbor mutations in genes related to DNA repair [25] and recent clinical trials suggested the benefit of PARP inhibitor treatment for patients with platinum-sensitive pancreatic cancer genomic alterations in DNA repair genes beyond BRCA [26]. Here, PARP1 is linked to pancreatic neoplasm.